Vaxart Inc reports results for the quarter ended December 31 - Earnings Summary
20/03/2025 21:01
Vaxart Inc VXRT.OQ reported a quarterly adjusted loss of 5 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of three analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -11 cents to -8 cents per share. Revenue rose 368% to $15.19 million from a year ago; analysts expected $20.77 million. Vaxart Inc's reported EPS for the quarter was a loss of 5 cents. The company reported a quarterly loss of $11.99 million. Vaxart Inc shares had fallen by 11.8% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy" Wall Street's median 12-month price target for Vaxart Inc is $4.00 This summary was machine generated from LSEG data March 20 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.10 | -0.05 | Beat |
| Sep. 30 2024 | -0.10 | -0.06 | Beat |
| Jun. 30 2024 | -0.03 | -0.09 | Missed |
| Mar. 31 2024 | -0.14 | -0.14 | Met |
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts